X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
male (11) 11
overactive bladder (11) 11
index medicus (10) 10
middle aged (10) 10
double-blind method (9) 9
urology & nephrology (8) 8
aged (7) 7
female (7) 7
urinary bladder, overactive - drug therapy (7) 7
treatment outcome (6) 6
mirabegron (5) 5
solifenacin (5) 5
urology (5) 5
administration, oral (4) 4
adult (4) 4
lower urinary tract symptoms (4) 4
severity of illness index (4) 4
solifenacin succinate (4) 4
acetanilides - therapeutic use (3) 3
adrenergic beta-3 receptor agonists - therapeutic use (3) 3
benign prostatic hyperplasia (3) 3
dose-response relationship, drug (3) 3
lower urinary tract symptoms - drug therapy (3) 3
muscarinic antagonists - administration & dosage (3) 3
muscarinic antagonists - therapeutic use (3) 3
single-blind method (3) 3
surveys and questionnaires (3) 3
thiazoles - therapeutic use (3) 3
urinary bladder, overactive - complications (3) 3
urinary bladder, overactive - diagnosis (3) 3
urinary bladder, overactive - physiopathology (3) 3
adolescent (2) 2
adrenergic alpha-1 receptor antagonists - administration & dosage (2) 2
adrenergic alpha-1 receptor antagonists - adverse effects (2) 2
aged, 80 and over (2) 2
benzhydryl compounds - therapeutic use (2) 2
beta-adrenoceptor (2) 2
beta-adrenoceptor agonist (2) 2
bladder outlet obstruction (2) 2
cancer (2) 2
clinical trials (2) 2
cresols - therapeutic use (2) 2
delayed-action preparations - therapeutic use (2) 2
double-blind (2) 2
drug combinations (2) 2
drug therapy (2) 2
efficacy (2) 2
expression (2) 2
follow-up studies (2) 2
lower urinary tract symptoms - diagnosis (2) 2
lower urinary tract symptoms - physiopathology (2) 2
mirabegron-ym178-pharmacokinetics (2) 2
muscarinic antagonists - adverse effects (2) 2
oral controlled absorption system (2) 2
phenylpropanolamine - therapeutic use (2) 2
prostatic hyperplasia - drug therapy (2) 2
quality of life (2) 2
quinuclidines - administration & dosage (2) 2
quinuclidines - therapeutic use (2) 2
sulfonamides - administration & dosage (2) 2
sulfonamides - adverse effects (2) 2
tablets (2) 2
tamsulosin hydrochloride (2) 2
tamsulosin ocas (2) 2
tetrahydroisoquinolines - administration & dosage (2) 2
tetrahydroisoquinolines - therapeutic use (2) 2
tolterodine (2) 2
tolterodine tartrate (2) 2
trial (2) 2
urgency (2) 2
urinary incontinence (2) 2
urinary incontinence, urge - drug therapy (2) 2
urinary incontinence, urge - etiology (2) 2
urinary-tract symptoms (2) 2
urination - drug effects (2) 2
β3-adrenoceptor agonist (2) 2
absorption (1) 1
acetanilides - administration & dosage (1) 1
acetanilides - adverse effects (1) 1
acetanilides - blood (1) 1
acetanilides - pharmacokinetics (1) 1
acth analog (1) 1
acth analogue org 2766 (1) 1
adenocarcinoma - drug therapy (1) 1
adrenergic alpha-1 receptor antagonists - pharmacokinetics (1) 1
adrenergic beta-3 receptor agonists - administration & dosage (1) 1
adrenergic beta-3 receptor agonists - adverse effects (1) 1
adrenergic beta-3 receptor agonists - blood (1) 1
adrenergic beta-3 receptor agonists - pharmacokinetics (1) 1
adrenoceptor (1) 1
adrenoceptor agonist (1) 1
adrenocorticotropic hormone - administration & dosage (1) 1
adrenocorticotropic hormone - analogs & derivatives (1) 1
adrenocorticotropic hormone - therapeutic use (1) 1
alpha-adrenergic blocker (1) 1
anticonvulsants - administration & dosage (1) 1
anticonvulsants - therapeutic use (1) 1
antimuscarinic drugs (1) 1
aplasia vaginae (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Urogynecology Journal, ISSN 0937-3462, 09/2013, Volume 24, Issue 9, pp. 1447 - 1458
Journal Article
European Urology, ISSN 0302-2838, 2012, Volume 63, Issue 2, pp. 296 - 305
Abstract Background Despite several antimuscarinic treatment options for overactive bladder (OAB), there is still a need for distinct treatment approaches to... 
Urology | Tolterodine | Overactive bladder | Mirabegron
Journal Article
European Urology, ISSN 0302-2838, 2012, Volume 63, Issue 2, pp. 283 - 295
Abstract Background Mirabegron, a β3 -adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB). Objective To assess the efficacy... 
Urology | Mirabegron | β3-Adrenoceptor agonist | Overactive bladder (OAB) | Adrenoceptor agonist
Journal Article
EUROPEAN UROLOGY, ISSN 0302-2838, 02/2013, Volume 63, Issue 2, pp. 283 - 295
Journal Article
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 6, pp. 1003 - 1012
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 2, pp. 262 - 270
Abstract Background Short-term trials have demonstrated the efficacy and safety of combination therapy using antimuscarinics and α-blockers in men with lower... 
Urology | Muscarinic antagonist | Solifenacin | Benign prostatic hyperplasia | Clinical trial | Phase 3 | α-Adrenergic blocker | Tamsulosin OCAS | Lower urinary tract symptoms | TRIAL | OVERACTIVE BLADDER | UROLOGY & NEPHROLOGY | alpha-Adrenergic blocker | BLADDER OUTLET OBSTRUCTION | Tablets | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Urodynamics - drug effects | Male | Adrenergic alpha-1 Receptor Antagonists - administration & dosage | Urinary Retention - physiopathology | Urinary Bladder, Overactive - drug therapy | Urological Agents - adverse effects | Lower Urinary Tract Symptoms - drug therapy | Time Factors | Urinary Bladder, Overactive - physiopathology | Adrenergic alpha-1 Receptor Antagonists - adverse effects | Aged, 80 and over | Urological Agents - administration & dosage | Solifenacin Succinate - administration & dosage | Urinary Retention - drug therapy | Prostatic Hyperplasia - drug therapy | Urinary Bladder, Overactive - diagnosis | Double-Blind Method | Administration, Oral | Lower Urinary Tract Symptoms - physiopathology | Treatment Outcome | Chemistry, Pharmaceutical | Muscarinic Antagonists - administration & dosage | Prostatic Hyperplasia - diagnosis | Lower Urinary Tract Symptoms - diagnosis | Solifenacin Succinate - adverse effects | Sulfonamides - adverse effects | Urinary Bladder - physiopathology | Urinary Retention - diagnosis | Urinary Bladder - drug effects | Aged | Prostatic Hyperplasia - physiopathology | Drug Combinations | Sulfonamides - administration & dosage | Tamsulosin hydrochloride | Computer storage device industry
Journal Article
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, ISSN 0946-1965, 11/2012, Volume 50, Issue 11, pp. 838 - 849
Background and objectives: Mirabegron is a potent and selective beta(3)-adrenoceptor agonist in development for treatment of overactive bladder. Methods:... 
EFFICACY | oral controlled absorption system (OCAS) | RATS | SEX-RELATED DIFFERENCES | CANCER | beta-adrenoceptor | P-GLYCOPROTEIN | mirabegron-YM178-pharmacokinetics | PHASE-III TRIAL | YM178 | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | overactive bladder | EXPRESSION
Journal Article